<unk> , sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.<unk>  is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.<unk>  is the first drug to be awarded an "innovation passport" from the UK Medicines and Healthcare products Regulatory Agency (MHRA).<unk>  was approved for medical use in the United States in August 2021.<unk>  is the first hypoxia-inducible factor-2 alpha inhibitor therapy approved in the U.S.
Belzutifan
Ketotifen
Ginkgo biloba
Penmesterol
Bolesatine
Azeloprazole
Epiestriol
Viltolarsen